Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Alteogen issued a corrective disclosure to amend and postpone the merger schedule—including the EGM date, creditor objection period, merger date (December 31, 2024), and registration date—for the absorption merger between its subsidiaries Altos Biologics and Alteogen Healthcare.
📊 [Key Disclosure Details & Financial Highlights]
- Corrected Filing: Decision on Merger (Major Management Matters of Subsidiary) (Original Filing Date: 2024-11-07)
- Reason for Correction: Schedule adjustment due to changes in key dates such as the scheduled shareholders meeting date
- Target Subsidiary: Altos Biologics Corp. (CEO: Hee Jeong Ji, Main Business: Biopharmaceutical R&D, Major Subsidiary: Yes)
- Total Assets of Subsidiary: KRW 63.59B (24.83% of parent company’s consolidated total assets of KRW 256.10B)
- Method & Purpose of Merger: Absorption merger of Alteogen Healthcare Inc. (dissolved) by Altos Biologics Corp. (surviving) / Enhancing operational efficiency through organizational integration
- Merger Ratio: Altos Biologics Corp. : Alteogen Healthcare Inc. = 1.0000000 : 0.274192
- Key Correction Details (Schedule Adjustments):
- Scheduled Shareholders Meeting Date: (Before) 2024-11-22 ☞ (After) 2024-11-29
- Creditor Objection Period: (Before) 2024-11-23 ~ 2024-12-23 ☞ (After) 2024-11-30 ~ 2024-12-30
- Merger Date: (Before) 2024-12-24 ☞ (After) 2024-12-31
- Scheduled Merger Registration Date: (Before) 2024-12-30 ☞ (After) 2025-01-07
- Board Resolution Date: (Before) 2024-11-07 ☞ (After) 2024-11-14
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Completion of Revised Merger Timelines
This corrective filing reflects a postponement of approximately one week in the overall timeline for the intra-group absorption merger. Verifying whether subsequent procedures—including shareholder approvals and creditor objection processes—are successfully completed according to the revised merger date (December 31, 2024) and registration date is important to track corporate restructuring progress. Further updates can be confirmed in future corrective disclosures or upcoming periodic business reports on DART.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For inquiries regarding regulatory compliance or copyright requests, please contact ksb220805@gmail.com.
